OV16

Canadian Cancer Trials Group - Tumour Bank
Logged in as: Public
Location: Home - Disease Sites - - OV16

OV16 Details
Status: Closed
Activation Date: 2001AUG31
Closing Date: 2005JUN29
Phase: III

Description: A Phase III Study of Cisplatin Plus Topotecan Followed by Paciltaxel plus Carboplatin versus Paclitaxel plus Carboplatin as First Line Chemotherapy in Women with Newly Diagnosed Advanced Epithelial Ovarian Cancer

Eligibility: Patients with confirmed epithelial ovarian (or primary fallopian or peritoneal) cancer, Stage IIB to IV, with microscopic or macroscopic residual disease who have not received prior chemotherapy and have evidence of adequate organ function.

Objective: Primary: to compare progression free survival. Secondary: to compare overall survival, response rates, toxic effects, quality of life, and CA 125 normalization rates.

Participation: Not limited

Lay Description: The main purpose of this research study is to find out if first line treatment with four cycles of cisplatin combined with topotecan followed by another four cycles of paclitaxel combined with carboplatin will cause the tumour to shrink at least as well as, if not better than, standard treatment of paclitaxel combined with carboplatin given for eight cycles.

Primary Publication Show

Other Publications Show

Year: 2010
Title: Breast cancer protein expression as a prognostic marker in sporadic epithelial ovarian cancer: an NCIC CTG OV.16 correlative study
Authors: Weberpals JI;Tu D;Squire J;Islam S;Amin S;Pelletier L;O'Brien A;Hoskins P;Eisenhauer EA;
Reference: Journal of Clinical Oncology 2010 Jun 4 ; 28 (15s, abstr 5018)
Link: http://meetinglibrary.asco.org/content/49560-74

Year: 2011
Title: Breast cancer 1 (BRCA1) protein expression as a prognostic marker in sporadic epithelial ovarian carcinoma: an NCIC CTG OV.16 correlative study
Authors: Weberpals JI;Tu D;Squire JA;Amin MS;Islam S;Pelletier LB;O'Brien AM;Hoskins PJ;Eisenhauer EA;
Reference: Annals of Oncology 2011 Nov 1 ; 22 (11)
Link: http://annonc.oxfordjournals.org/content/22/11/2403.abstract

Year: 2016
Title: First application of the Automated QUantitative Analysis (AQUA) technique to quantify PTEN protein expression in ovarian cancer: A correlative study of NCIC CTG OV.16
Authors: Weberpals JI;Amin MS;Chen BE;Tu D;Spaans JN;Squire JA;Eisenhauer EA;Virk S;Ma D;Duciaume M;Hoskins P;LeBrun DP;
Reference: Gynecologic Oncology 2016 Mar 1 ; 140 (3)
Link: http://dx.doi.org/10.1016/j.ygyno.2016.01.015

Year: 2020
Title: Low junctional adhesion molecule-A expression is associated with an epithelial to mesenchymal transition and poorer outcomes in high-grade serous carcinoma of uterine adnexa
Authors: Communal L;Medrano M;Sircoulomb F;Paterson J;Kobel M;Rahimi K;Hoskins P;Tu D;Lheureux S;Oza A;Ailles L;Provencher D;Rottapel R;Mes-Masson AM;
Reference: 2020 Nov ; 33 (11)
Link: https://doi.org/10.1038/s41379-020-0586-0

Year: 2023
Title: CA-125 Early Dynamics to Predict Overall Survival in Women with Newly Diagnosed Advanced Ovarian Cancer Based on Meta-Analysis Data
Authors: Karamouza E;Glasspool RM;Kelly C;Lewsley LA;Carty K;Kristensen GB;Ethier JL;Kagimura T;Yanaihara N;Cecere SC;You B;Boere IA;Pujade-Lauraine E;Ray-Coquard I;Proust-Lima C;Paoletti X;
Reference: Cancers 2023 Mar 17; 15 (6)
Link: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10047009/

Inventory
Hide Tissue Samples

Disease Site	Trial Code	Patients Accrued	Patients - Blocks	Patients - Slides	Patients - Blocks and/or Slides
GYNECOLOGIC	OV16	819	318	362	367

Hide TMA Samples

(Core size is 0.6 mm)

Disease Site	Trial Code	Patients Accrued	TMA Blocks	Patients on TMA Blocks
GYNECOLOGIC	OV16	819	9	301

Hide Fluid Samples

Disease Site	Trial Code	Patients Accrued	Patients - Whole Blood	Patients - Cellular Component of Blood	Patients - DNA extracted from Blood	Patients - RNA extracted from Blood	Patients - Plasma	Patients - Serum	Patients - Urine	Patients - Buccal
GYNECOLOGIC	OV16	819	0	0	0	0	0	0	0	0